Result of General Meeting and Change of Name

RNS Number : 8241D

Epistem Holdings plc

11 July 2016

 

 11 July 2016

Epistem Holdings plc ("Epistem" or the "Company")

Result of General Meeting and Change of Name

Epistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, announces that at the General Meeting held earlier today, all the resolutions proposed were duly passed.  The Company will within the next 15 days formally change its name to Genedrive plc and the TIDM will change to GDR.  The Company will make a further announcement at that time.

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 23 June 2016 which is available on the Company's website http://www.epistem.co.uk/.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 8,125,000 New Ordinary Shares.  It is expected that Admission will become effective at 8.00 a.m. on 12 July 2016.  Following Admission, the Company will have 18,689,446 Ordinary Shares in issue.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.

For further details please contact:

Epistem Holdings Plc	[phone]
David Budd: CEO
John Rylands: Finance Director
Peel Hunt LLP	[phone]
James Steel
Oliver Jackson
Sohail Akbar
Consilium Strategic Communications	[phone]
Chris Gardner
Laura Thornton
[e-mail]

Notes to Editors

About Epistem

Epistem is a personalised medicine and biotechnology company developing innovative molecular diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and its MTB/RIF test has been launched in India. Further details can be found at: www.epistem.co.uk and www.genedrive.com

 

END

 

 

MSCLLFVIDVILLIR